Wealth Architects’s Co-Diagnostics CODX Stock Holding History

Wealth Architects’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,333	Closed	-$305K	–	145
2020 Q1	$305K	Buy	+1,333	New	+$231K	0.11%	95

Other funds holding CODX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wealth Architects's CODX Position: Q2 2020 in Review

Wealth Architects sold out of Co-Diagnostics (CODX) in Q2 2020, closing a stake of 1,333 shares — an estimated $305K sold.

Wealth Architects first reported a position in CODX in Q1 2020 and held it in 1 quarter. The position peaked at $305K in Q1 2020. 86 funds tracked by Wall St. Rank hold CODX as of Q2 2020.

Wealth Architects reported no remaining Co-Diagnostics position as of Q2 2020 after selling out during the quarter.
Wealth Architects sold 1,333 Co-Diagnostics shares in Q2 2020, an estimated $305K.
Wealth Architects first reported a position in Co-Diagnostics in Q1 2020 and held it in 1 quarter.
Wealth Architects's Co-Diagnostics position peaked at $305K in Q1 2020.
86 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2020.

Based on Wealth Architects's 13F filing for Q2 2020, filed 14 Aug 2020.